Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.
Nair R, Vu A, Freer AK, Bhatia KS, Wang D, Savani MR, Matulis SM, Lonial S, Jaye DL, Boise LH, Seo SY, Corson TW, Nooka AK, Bhatt S, McBrayer SK, Gupta VA, Hu X, Barwick BG, Reddi AR, Shanmugam M. Nair R, et al. Among authors: nooka ak. Blood. 2024 Dec 18:blood.2024025690. doi: 10.1182/blood.2024025690. Online ahead of print. Blood. 2024. PMID: 39693611
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
van de Donk NWCJ, Bahlis N, Costa LJ, Mateos MV, Nooka AK, Perrot A, Garfall AL, Thaman P, Qi K, Uhlar C, Chastain K, Doyle M, Usmani SZ. van de Donk NWCJ, et al. Among authors: nooka ak. Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1. Blood Cancer J. 2024. PMID: 39433732 Free PMC article. No abstract available.
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Chung DJ, et al. Among authors: nooka a. Clin Cancer Res. 2024 Oct 1;30(19):4542. doi: 10.1158/1078-0432.CCR-24-2408. Clin Cancer Res. 2024. PMID: 39350638 Free PMC article. No abstract available.
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Joseph NS, Kaufman JL, Gupta VA, Hofmeister CC, Dhodapkar MV, Boise LH, DiCamillo SM, Roberts D, Nooka AK, Lonial S. Joseph NS, et al. Among authors: nooka ak. Blood Cancer J. 2024 Sep 13;14(1):159. doi: 10.1038/s41408-024-01120-9. Blood Cancer J. 2024. PMID: 39271684 Free PMC article.
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodríguez-Otero P. Ailawadhi S, et al. Among authors: nooka ak. Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582. Blood. 2024. PMID: 39197072 Clinical Trial.
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Touzeau C, et al. Among authors: nooka ak. Blood. 2024 Dec 5;144(23):2375-2388. doi: 10.1182/blood.2023023616. Blood. 2024. PMID: 39172760 Clinical Trial.
Improving reporting of infection events in clinical trials.
Ludwig H, Munshi NC, Terpos E, Raje N, Moreau P, Nooka A. Ludwig H, et al. Among authors: nooka a. Blood Adv. 2024 Nov 26;8(22):5927-5928. doi: 10.1182/bloodadvances.2024014102. Blood Adv. 2024. PMID: 39110989 Free PMC article. No abstract available.
Single-cell transcriptome atlases of soybean root and mature nodule reveal new regulatory programs that control the nodulation process.
Cervantes-Pérez SA, Zogli P, Amini S, Thibivilliers S, Tennant S, Hossain MS, Xu H, Meyer I, Nooka A, Ma P, Yao Q, Naldrett MJ, Farmer A, Martin O, Bhattacharya S, Kläver J, Libault M. Cervantes-Pérez SA, et al. Among authors: nooka a. Plant Commun. 2024 Aug 12;5(8):100984. doi: 10.1016/j.xplc.2024.100984. Epub 2024 Jun 6. Plant Commun. 2024. PMID: 38845198 Free PMC article.
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Among authors: nooka a. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28. Lancet Oncol. 2024. PMID: 38821074 Review.
192 results